The Staphylococcus genus includes at least 40 species. Of these, nine have two subspecies, one has three subspecies, and one has four subspecies (
1). Most are harmless and reside normally on the skin and mucous membranes of humans and other organisms. Found worldwide, they are a small component of soil microbial flora (
2). Coagulase-negative staphylococci (CoNS) species make up a large and heterogeneous group of Gram-positive bacteria, into which more than 30 species have been introduced (
3,
4).
In recent years, the importance of CoNS has increased, especially because of their major causative role in the nosocomial infections in both developed and developing countries (
5,
6). The widespread use of immunosuppressive drugs, indwelling intravascular catheters, artificial tools, patient- and personnel-related factors, and health-care settings have been reported to be associated with the spread of these infections (
7). Premature infants are at a high risk of CoNS infections (
6).
Among the CoNS,
S. epidermidis,
S. haemolyticus and
S. saprophyticus are more common in nosocomial infections, most of which have gained resistance to methicillin, penicillin, and other antibiotics (
8). The genes responsible for the multi-drug resistance (MDR) phenotype of CoNS are located on plasmids, which can be easily exchanged between the species. Indeed, despite continuing efforts, antibiotic resistance remains a major problem in controlling the CoNS infections (
9). To achieve effective treatment, a variety of glycopeptide antibiotics, including vancomycin, teicoplanin, telavancin, ramoplanin, and decaplanin are primarily prescribed (
10). Vancomycin is the most important drug for treatment of the MDR
S. epidermidis (
11). However, resistance to vancomycin has been frequently reported among the staphylococci (
12,
13). In 1987, Schwalbe and colleagues reported the first clinical isolate of vancomycin-resistant CoNS (
13). Since then, many vancomycin-resistant or other glycopeptide-resistant CoNS isolated from clinical samples have been documented in different countries (
14-
18). Additionally, the emergence of resistance to teicoplanin has been reported (
15). Therefore, the use of vancomycin and teicoplanin as appropriate therapeutic agents against CoNS infections is under debate (
19).